Clinical trial NCT00079261 (phase 2, status: completed)
Conditions: lymphoma, small intestine cancer
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C17.9, C78.4, D37.2, C17.8, D13.30, D13.39, Z12.13
Drugs: chop regimen, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, prednisone, vincristine sulfate
SMILES: CCO, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) of 1 of the following
             WHO subtypes:

               -  Diffuse large B large cell lymphoma (including all clinical and morphologic
                  variants)

               -  Grade 3 follicular lymphoma

               -  Extranodal T/NK cell lymphoma, nasal type

               -  Enteropathy-type T cell lymphoma

               -  Hepato-splenic T cell lymphoma

               -  Peripheral T cell lymphoma, unspecified

               -  Angioimmunoblastic lymphoma

               -  Anaplastic large cell lymphoma, systemic type

          -  Stage II-IV disease

          -  At least 1 site of measurable disease (e.g., lymph node or lymph node mass)

          -  The following subtypes are not allowed:

               -  Mantle cell lymphoma

               -  Burkitt's lymphoma

               -  Precursor B or T cell lymphoma

               -  Primary cutaneous B or T cell lymphoma

          -  No CNS involvement by lymphoma

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 70

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC > 3,000/mm^3

          -  Neutrophil count > 1,000/mm^3

          -  Platelet count > 100,000/mm^3

        Hepatic

          -  Bilirubin < 2.5 times normal (unless due to lymphoma)

          -  ALT and AST < 2.5 times normal (unless due to lymphoma)

        Renal

          -  Creatinine < 2.0 mg/dL

        Cardiovascular

          -  No severe cardiac disease that would preclude study participation or limit life
             expectancy

        Pulmonary

          -  FEV_1 and DLCO ≥ 75% of predicted (unless due to lymphoma)

          -  No severe pulmonary disease that would preclude study participation or limit life
             expectancy

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other prior or concurrent malignancy except basal cell skin cancer or carcinoma in
             situ of the cervix

          -  No severe neurologic or metabolic disease that would preclude study participation or
             limit life expectancy

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent monoclonal antibodies

        Chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  No prior cytotoxic agents

          -  No prior treatment for NHL

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational drugs